1. Home
  2. INKT vs MRNS Comparison

INKT vs MRNS Comparison

Compare INKT & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • MRNS
  • Stock Information
  • Founded
  • INKT 2017
  • MRNS 2003
  • Country
  • INKT United States
  • MRNS United States
  • Employees
  • INKT N/A
  • MRNS N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • MRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • INKT Health Care
  • MRNS Health Care
  • Exchange
  • INKT Nasdaq
  • MRNS Nasdaq
  • Market Cap
  • INKT 36.7M
  • MRNS 29.9M
  • IPO Year
  • INKT 2021
  • MRNS 2014
  • Fundamental
  • Price
  • INKT $9.38
  • MRNS $0.55
  • Analyst Decision
  • INKT Strong Buy
  • MRNS Buy
  • Analyst Count
  • INKT 2
  • MRNS 12
  • Target Price
  • INKT $6.50
  • MRNS $4.28
  • AVG Volume (30 Days)
  • INKT 72.2K
  • MRNS 1.2M
  • Earning Date
  • INKT 03-20-2025
  • MRNS 03-04-2025
  • Dividend Yield
  • INKT N/A
  • MRNS N/A
  • EPS Growth
  • INKT N/A
  • MRNS N/A
  • EPS
  • INKT N/A
  • MRNS N/A
  • Revenue
  • INKT N/A
  • MRNS $31,466,000.00
  • Revenue This Year
  • INKT N/A
  • MRNS $14.97
  • Revenue Next Year
  • INKT N/A
  • MRNS $57.65
  • P/E Ratio
  • INKT N/A
  • MRNS N/A
  • Revenue Growth
  • INKT N/A
  • MRNS 1.63
  • 52 Week Low
  • INKT $4.56
  • MRNS $0.22
  • 52 Week High
  • INKT $19.00
  • MRNS $10.50
  • Technical
  • Relative Strength Index (RSI)
  • INKT 51.78
  • MRNS 70.71
  • Support Level
  • INKT $7.32
  • MRNS $0.54
  • Resistance Level
  • INKT $13.79
  • MRNS $0.55
  • Average True Range (ATR)
  • INKT 2.00
  • MRNS 0.00
  • MACD
  • INKT 0.05
  • MRNS -0.01
  • Stochastic Oscillator
  • INKT 52.22
  • MRNS 100.00

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

About MRNS Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Share on Social Networks: